VC fund profile · evidence-aware directory data
Advent Life Sciences Growth Fund stages, portfolio and investment profile
Separate life-sciences growth vehicle focused chiefly on UK clinical development and commercial scale-up. British Business Bank committed approximately €87.2M on September 24, 2026. It lists a fundraising target of approximately €233M–€349M, not a verified first/final close or completed fund size.
Keep track of Advent Life Sciences Growth Fund
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$1M–$10M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Not recorded
Participates: Series B, Series B+, Series C, Growth
Sector focus
Not recorded
Geography
London, UK
Founded Not recorded
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
None yet
Linked startup profiles
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
VCT investor research
Inside Advent Life Sciences Growth Fund's investment strategy
Independent, source-backed analysis of who the firm backs, deal evidence and whether it fits your stage.
Mandate
Advent's distinct growth vehicle targets later clinical-stage healthcare companies and nontherapeutic products with initial commercial traction, primarily in the UK. This differs from Fund IV's early-stage mandate.
Disclosed commitments vs fund size
On September 24, British Business Bank confirmed its commitment equivalent to approximately €87.2M at the contemporaneous ECB fixing. Its vehicle page gives a €233M–€349M fundraising target, not an amount already closed. No confirmed GP first/final close date, completed fund amount, other LP roster or fee/carry schedule has been published in these primary documents.
Practical founder tour
An illustrative clinical-stage founder would present trial endpoints, recruitment and risk, regulatory plan, runway to readout and manufacturing requirements. For nontherapeutic products, validation includes actual paying customers, sales economics and reimbursement where relevant. The public strategy does not specify minimum check size or guaranteed funding process.
Related Advent Life Sciences; Fund IV. Sources: Bank statement; Growth Fund listing; ECB.
Sources and verification
Dated company disclosures take priority over third-party databases. These sources support the analysis above.
Rounds they lead
Rounds they invest
Last verified: Not recorded. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.